Inactivation of p53 and p73 is known to promote thyroid cancer progression. We now describe p63 expression and function in human thyroid cancer. TAp63a is expressed in most thyroid cancer specimens and cell lines, but not in normal thyrocytes. However, in thyroid cancer cells TAp63a fails to induce the target genes (p21Cip1, Bax, MDM2) and, as a consequence, cell cycle arrest and apoptosis occur. Moreover, TAp63a antagonizes the effect of p53 on target genes, cell viability and foci formation, and p63 gene silencing by small interfering (si) RNA results in improved p53 activity. This unusual effect of TAp63a depends on the protein C-terminus, since TAp63b and TAp63g isoforms, which have a different arrangement of their C-terminus, are still able to induce the target genes and to exert tumour-restraining effects in thyroid cancer cells. Our data outline the existence of a complex network among p53 family members, where TAp63a may promote thyroid tumour progression by inactivating the tumour suppressor activity of p53. Endocrine-Related Cancer (2005) 12 953-971 Endocrine-Related Cancer (2005) 12 953-971 Endocrine-Related Cancer (2005) 12 953-971
Introduction
Thyroid cancer is a common endocrine malignancy and several genetic abnormalities have been identified in the different thyroid cancer histotypes, involving both oncogenes and tumour suppressor genes. Mutations in proto-oncogenes (Ret, BRAF, Ras) are often observed in well-differentiated thyroid tumours (papillary and follicular) (Fagin 2002) . Indeed, Ret/PTC rearrangements and BRAF mutations are observed in approximately 10-50% of papillary thyroid cancer, whereas Ras mutations are observed in approximately 20-50% of follicular thyroid cancer (Gimm 2001) .
Tumour suppressor gene abnormalities, responsible for thyroid tumour progression, involve PTEN, b-catenin and p53. Decreased PTEN expression, presumably by loss of heterozygosity, has been observed in papillary (10%), follicular (15%) and poorly differentiated thyroid carcinomas (60%), whereas b-catenin mutations have been found in approximately 60% of anaplastic thyroid carcinomas (Gimm 2001) . More specifically, p53 mutations are found in more than 80% of the poorly differentiated (anaplastic) thyroid carcinomas (Fagin et al. 1993) . As a consequence, loss of p53 function is believed to play an important role in thyroid tumour progression from well (papillary and follicular) to poorly (anaplastic) differentiated thyroid cancer (Fagin et al. 1993) . Moreover, several reports have shown that, even in the absence of inactivating mutations, the p53 protein is inactive in certain thyroid tumours and cell lines (Wyllie et al. 1995 , Nishida et al. 1996 , suggesting that other mechanisms may be responsible for p53 inactivation in these tumours. Finally, up-regulation of non-mutated p53 protein has been related to a poor clinical outcome in thyroid cancer (Dobashi et al. 1993 , Nishida et al. 1996 , Ruter et al. 1996 .
Two novel members have been added to the p53 family: p63 (Yang et al. 1998 ) and p73 (Kaghad et al. 1997) . These proteins have remarkable similarities in both structure and function to p53, since they can transactivate p53-responsive genes including p21Cip1, Bax and MDM2, and induce cell cycle arrest and apoptosis (Jost et al. 1997 , Kaghad et al. 1997 , Yang et al. 1998 .
In addition to the transcriptionally active (full length) TAp63 and TAp73 isoforms, p63 and p73 genes, by the use of an inner promoter located in intron 3, may generate the DNp63 and DNp73 variants, which are N-terminally truncated and exert a dominant negative effect towards p53, TAp63 and TAp73 (Yang et al. 1998 , Pozniak et al. 2000 . Furthermore, p63 and p73 may undergo multiple C-terminal splicing, generating at least six isoforms for p73 (a, b, g, d, e, j) (Kaghad et al. 1997 , De Laurenzi et al. 1998 , Zaika et al. 1999 , and three isoforms for p63 (a, b, g) (Yang et al. 1998) . At variance with p53 null mice, however (Donehower et al. 1992) , p63 and p73 knockout mice do not develop spontaneous tumours (Mills et al. 1999 , suggesting that p63 and p73 function is not strictly related to tumour suppressor activity. Moreover, attempts to identify mutations in the p63 and p73 gene in human cancers have been largely unsuccessful. More interestingly, several cancers overexpress the dominant negative isoforms DNp63 and DNp73 (Zaika et al. 1999 (Zaika et al. , 2002 and data obtained from fibroblasts in vitro suggest that DNp63 and DNp73 may display an oncogenic potential (Hibi et al. 2000 , Petrenko et al. 2003 .
We have shown that thyroid cancer cells express DNp73a and TAp73a . In these cells, TAp73a tumour suppressor activity is kept latent by several mechanisms including the cytoplasmic entrapment of c-Abl , interaction with p53 mutants and DNp73a .
In the present study, we explored the role of p63 in thyroid tumours and found that TAp63a is expressed in most thyroid cancers but not in the normal thyroid or in follicular adenomas, and it may represent, therefore, a marker of malignancy. In thyroid cancer cells, TAp63a does not elicit p53-like responses. In contrast, TAp63a exerts an unexpected inhibitory effect on the tumour suppressor activity of p53. The absence of TAp63a tumour suppressor activity and the presence of an anti-p53 effect suggest a role for p63 in thyroid tumour progression.
Materials and methods

Cells
The human thyroid cancer cell lines (see Table 2 ) BC-PAP (papillary) and FRO (follicular) were provided by Drs A Fusco and M Santoro (Naples, Italy); SW-1736 (anaplastic), Hth-74 (anaplastic) and C-643 (anaplastic) cells were provided by Dr N E Heldin (Uppsala, Sweden); FF-1 (anaplastic) and AM-1 (anaplastic) cells were established in our laboratory; 8505-C (papillary) cells were purchased from DMSZ (Braunschweig, Germany); FTC-133 (follicular) and 8305-C (anaplastic) cells were purchased from ECACC (Salisbury, Wilts, UK); C-98 cells, a clone harbouring a mutation in the p53 gene, were established from TPC-1 (a papillary thyroid cancer cell line provided by Dr A Fusco, Naples, Italy). All thyroid cancer cell lines (see Table 2 ) were grown in RPMI 1640 (Sigma, St Louis, MO, USA) supplemented with 2 mM glutamine, 10% FBS and 100 mg penicillin and streptomycin/ml. Normal thyroid cells in primary culture were obtained from surgical specimens after treatment with 1 mg collagenase IV/ml (Sigma). The human osteosarcoma cell line, Saos-2, and the simian kidney cell line, COS-1, were provided by Dr J Y Wang (La Jolla, CA, USA) and cultured in DMEM (Sigma) supplemented with 10% FBS, and 100 mg penicillin and streptomycin/ml. The human breast cancer cell line, MCF-7 (ATCC, Manassas, VA, USA), and the human oesophagus carcinoma cell line, A431 (Dr Weir, Boston, MA, USA), were grown in MEM supplemented with FBS and antibiotics as described above.
Human thyroid tissue samples
Human thyroid cancer specimens were obtained at surgery and stored in liquid nitrogen until processing.
Immunohistochemistry
In order to set up this technique, p63-positive (FTC-133 and C-643) and p63-negative (C-98) (see Fig. 2 ) thyroid cancer cells were grown in monolayers, harvested by trypsinization, and centrifuged at 270 g for 10 min at 4 C. As a positive control, we used the A431 oesophagus cancer cell line, which expresses p63 at a higher level than thyroid cancer cells (see Fig. 2B ). Cell pellets were immediately frozen in liquid nitrogen or, alternatively, fixed with paraformaldehyde and paraffin embedded. From these pellets were obtained 7 mm-thick sections of both fixed and unfixed cells, which were subjected to immunohistochemical staining for p63 and p53. In these experiments in A431 cells, p63 was detected in both frozen and paraffin-embedded sections. In contrast, in p63positive thyroid cancer cells, p63 immunostaining was observed only in frozen sections, but not in paraffinembedded sections. Thyroid tissue sections were cut with a cryostat at x30 C, fixed with acetone at x20 C for 10 min and hydrated with PBS at room temperature for 45 min. After blocking in 2% normal serum for 20 min, sections were incubated overnight with the anti-pan-p63 monoclonal antibody 4A4 (1 : 100) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), the anti-p63g goat polyclonal antibody C-18 (1 : 100) (Santa Cruz Biotechnology) or the anti-p53 monoclonal antibody DO-1 against the N-terminus of p53 (1 : 200) (Santa Cruz Biotechnology). Specific labelling was detected with biotin-conjugated antimouse/anti-rabbit/anti-goat IgG and avidin-biotin peroxidase complex. Sections were counterstained with either haematoxylin QS or Nuclear Fast Red (NFR), examined and photographed using an Olympus BH-2 microscope. In every experiment, sections were incubated with secondary antibody alone to further verify the specificity of the reaction.
Immunofluorescence
Cells were fixed in 3.7% formaldehyde, permeabilized with PBS/0.3% Triton X-100, blocked with PBS/10% normal goat serum and incubated with primary antibodies for 1 h. To detect endogenous p63 we used the anti-pan-p63 monoclonal antibody 4A4 (Santa Cruz Biotechnology). To detect transfected p63 we used the anti-MycTag monoclonal antibody 9E10 (Santa Cruz Biotechnology). Cells were then incubated with Alexa-conjugated (Alexa Fluor 594 or 488) secondary antibodies (Molecular Probes, Leiden, The Netherlands) for 1 h. To visualize the cytoplasm, the cells were also incubated with Alexa-conjugated phalloidin (Molecular Probes) for an additional 30 min. The cells were finally counterstained with Hoechst (Sigma) to colour the nuclei. Epifluorescence microscopy was performed with an Olympus microscope. The images were digitally acquired with an Orca CCD camera (Hamamatsu, Hamamatsu City, Japan) and processed with Image-Pro Plus 4.0 software (Media Cybernetics, Silver Spring, MD, USA).
Immunoprecipitation and immunoblot analysis
Cell lysates were prepared in RIPA buffer containing 0.1% SDS and protease inhibitor cocktail (Roche Biochemical Inc., Basel, Switzerland). For immunoprecipitation experiments, 1 mg cell lysate was incubated for 2 h with 2 mg antibody. After incubation with protein A-Sepharose (Amersham Biosciences, Uppsala, Sweden), samples were resuspended in loading buffer, separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% milk-Tris-buffered saline plus Tween (TBST) and then immunoblotted with primary antibodies (1 mg/ml). Appropriate horseradish-peroxidase-conjugated secondary antibodies were added at 1 : 2000 (Amersham Biosciences), and proteins were visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA).
The following antibodies were used for immunoprecipitation: polyclonal anti-p63a antibody H129, polyclonal anti-pan-p63 H137 and monoclonal antibody DO-1 against the N-terminus of p53 (all from Santa Cruz Biotechnology). The following antibodies were used for western blotting: anti-pan-p63 monoclonal antibody 4A4 (Santa Cruz Biotechnology), anti-p53 monoclonal antibody DO-1 (Santa Cruz Biotechnology), anti-p21Cip1 polyclonal antibody (Santa Cruz Biotechnology), anti-b-actin monoclonal antibody (Sigma), anti-GFP monoclonal antibody (Covance Research Product Inc. Princeton, New Jersey, USA) and anti-Myc monoclonal antibody 9E10 (Santa Cruz Biotechnology).
Transcript analysis by RT-PCR
Total RNA (1 mg) was reverse transcribed with Superscript II (Invitrogen, Paisley, Strathclyde, UK) and oligo(dT) primers. Of the synthesized cDNA 2 ml were then combined in a PCR specific for p63a and b, using primers 5 0 CGT ACA GGC AAC AGC AAC A 3 0 (forward) and 5 0 CGT TGC GCT GCT GAG GGT TGA 3 0 (reverse) spanning exons 10 and 14 of the p63 gene (fragment size 632 bp). The TAp63 transcript was detected using primers 5 0 CCC AGA GCA CAC AGA CAA A 3 0 (forward) and 5 0 CAC AGA TCC GGG CCT CAA A 3 0 (reverse) spanning exons 2 and 8 (fragment size 896 bp). The p63g transcript was detected using primers 5 0 ATG CCC AGT ATG TAG AAG A 3 0 (forward) and 5 0 GGG CTT GGA ATG TCT AAA G 3 0 (reverse) spanning exons 6 and 15 of the p63 gene (fragment size 697 bp), and the DNp63 transcript was detected using primers 5 0 AAC AAT GCC CAG ACT CAA 3 0 (forward) and 5 0 ACA GGC ATG GCG CGG ATA 3 0 (reverse) spanning intron 3 and exon 5 (fragment size 392 bp).
Plasmids and transfections
pBOS-H2B-GFP and pCDNA3.1-p53 were provided by Dr J Y Wang (La Jolla, CA, USA); All transfections were performed in 6-well plates with Fugene 6 (Roche Biochemical Inc., Basel, Switzerland) according to the manufacturer's instructions (DNA : Fugene ratio 1 : 3), and cells were processed 24 h after transfection.
We tested the onco-suppressor effect of p53 and p63 constructs by evaluating the reduction of the number of transfected cells (apoptosis plus inhibition of cell growth) as previously reported (Ozaki et al. 2003) . We transfected p53 and p63 constructs (2 mg/ well) together with H2B-GFP (0.2 mg/well). Forty-eight hours after transfection, the GFP-positive cells were scored under a fluorescence microscope and numbers obtained were expressed as a percentage of GFPpositive cells among the total population and were compared with the empty-transfected cells.
Luciferase assay
The p21Luc, BaxLuc and MDM2Luc constructs were co-transfected with pCDNA3.1, pCDNA3.0-Myc-TAp63a, pCDNA3.0-Myc-TAp63b, pCDNA3.0-Myc-TAp63g, pCDNA3.0-Myc-DNp63a and pCDNA3.1-p53 (DNA ratio 1 : 1). A vector coding for the Renilla luciferase (provided by Dr E Conte, Catania, Italy) was also co-transfected in all conditions (DNA ratio 1 : 20). Twenty-four hours after transfection, the cells were processed with the Dual Luciferase assay (Promega Corp., Madison, WI, USA) according to the manufacturer's instructions. Luciferase activity was normalized for transfection efficiency (Renilla activity).
Gene silencing by siRNA
Cells were plated onto 6-well plates (10 5 cells/well) and kept in antibiotic-free medium for 24 h. Cells were then transfected with a mixture containing OptiMEM, 8 ml lipofectamine/well (Lipofectamine 2000, Invitrogen) and either 0.5 mg GFP-small interfering (si) RNA or 0.5 mg TAp63-siRNA/well (Dharmacon Research Inc., Lafayette, CO, USA) for 5 h. The sequence of these siRNAs is available from the manufacturer. Cells were then incubated with fresh medium for 48 h and transfected with p53 (0.5-1.0 mg/well) together with p21-luc (1.0 mg) and Renilla (0.2 mg), using Fugene 6 reagent (Roche). Twenty-four hours after transfection, cell extracts were analysed for p21 activity by the luciferase assay. Aliquots of these samples were also subjected to western blot for the assessment of p63 status.
Cell cycle evaluation
Cells were synchronized for 36 h in serum/leucine-free medium and released in complete medium for 12 h (cell cycle) or 72 h (apoptosis) in the presence or absence of 2 mM doxorubicin. Adherent and floating cells were harvested and resuspended in 70% ethanol and stored at x20 C. Permeabilized cells were centrifuged and resuspended in PBS containing 20 mg Propidium Iodine (PI)/ml plus 40 mg RNAse/ml (Sigma) for 30 min in the dark. Cells were then subjected to FACS analysis (Coulter Elite flow cytometer, Beckman Coulter, Milan, Italy) and gated for PI (X axis = FL2; Y axis = events). To evaluate the subG1 population, a log scale was applied to the X axis (PI, FL2). Cells transfected with GFP-tagged constructs were not treated with 70% ethanol so as to avoid GFP denaturation and, as a consequence, loss of fluorescent emission. GFP-containing cells were fixed instead with 1% paraformaldehyde in PBS for 2 h at 4 C and permeabilized with 0.3% Triton in PBS for 20 min at room temperature or, alternatively, treated with citrate hypotonic buffer. Triton-permeabilized cells were incubated with PI and RNAse overnight at 4 C, whereas citrate-permeabilized cells were incubated with PI and RNAse for 30 min at room temperature in the dark. Cells were than subjected to FACS analysis and gated for PI (FL2) and GFP (FL1). Cell cycle analysis was performed by placing separate gates in both the transfected (GFP positive), and untransfected (GFP negative) population. The percentage of GFP-positive cells ranged from 2 to 20% of total cells. For GFP-positive cells at least 10 4 events were counted.
Foci formation
C-98, BC-PAP, SW-1736 and C-643 thyroid cancer cells were plated onto 6-well plates (10 5 cells/well) in complete 10% FCS medium. After 24 h, each well was transfected using the Fugene 6 method (Roche) with either 2 mg empty vector, or a mixture containing 1 mg empty+1 mg p53, 1 mg empty+1 mg TAp63a, 1 mg empty+1 mg DNp63a, 1 mg p53+1 mg TAp63a, or 1 mg p53+1 mg DNp63a. Cells were allowed to grow until 90% confluent and were split onto 100 mm Petri dishes. Cells were then grown in complete medium containing G418 (Gibco) (concentration range 0.5-1.0 mg/ml, depending on the cell line) to allow antibiotic (geneticin) selection. The foci obtained with this procedure were fixed in 11% glutaraldehyde, stained with Crystal Violet (BDH, Poole, Dorset, UK) and counted.
Statistical analysis
FACS analysis results were compared by two-way analysis of variance. Significance was obtained by Student's t-test (*P<0.05, **P<0.01, ***P<0.001). Statistical analysis was carried out with Microsoft Excel software.
Results
TAp63a is expressed in human thyroid cancer tissue
Previous studies performed in paraffin-embedded specimens indicated that p63 is expressed in a small subset of papillary and anaplastic thyroid carcinomas (Preto et al. 2002) . We examined 23 frozen thyroid specimens by immunohistochemistry (IHC) ( Fig. 1A , Table 1 ) using the anti-pan-p63 4A4 antibody. In these experiments, p63 immunoreactivity was present in most thyroid cancers (9/9 papillary carcinomas, 7/7 follicular carcinomas, 9/11 anaplastic carcinomas) ( Table 1 ). In contrast, p63 was not detected in normal thyroid (n = 8), whereas it was detected in 1 out of 7 benign adenomas (Table 1) . p63 was also detected in vessels of both normal and neoplastic thyroid tissue ( Fig. 1A , right panel). In thyroid cancer cells, p63 immunoreactivity was mostly localized in the nucleus (Table 1) . Immunohistochemistry with a specific anti-p63g antibody gave negative results (not shown) and immunohistochemistry in paraffin-embedded tissues provided a weak signal only in a small percentage of thyroid specimens, in accordance with the previous observations (Preto et al. 2002) . Since the 4A4 antibody used in these experiments recognizes all p63 isoforms, we studied p63 isoform expression in frozen thyroid tissue specimens by RT-PCR ( Fig. 1B) . As a negative control we used C-98 thyroid cancer cells (p63 negative, see Table 2 ), while as a positive control we used the oesophagus cancer cell line A431 (Kaelin 1999) . In thyroid cancer specimens, we detected the TAp63a transcript but found no mRNA for TAp63b, TAp63g and DN-p63 ( Fig. 1B) . TAp63a transcript was also found in normal thyroid tissues; its expression, in accordance with the IHC results, must be attributed to the presence of p63 immunoreactivity in blood vessels (Fig. 1A ). In the same samples, we then evaluated p63 protein expression by immunoprecipitation with the anti-pan-p63 antibody (H137) and by western blot analysis with the anti-pan-p63 antibody (4A4) (Fig. 1C ). As a positive control we used lysates of COS-1 cells transfected with TAp63a, TAp63g or DNp63a (Fig. 1C ). In accordance with the RT-PCR results, we found that in thyroid cancer specimens only the TAp63a protein was expressed (Fig. 1C) . In contrast to malignant tissue, TAp63a protein was not detected in normal thyroid tissues (Fig. 1C, left panel) . Taken together, these data indicate that the TAp63a protein is expressed in most thyroid cancer cells but not in normal thyroid or in follicular adenoma cells. The apparent contrast of the TAp63a transcript presence in normal thyroid is due to the TAp63a expression in endothelial cells. It is also interesting to note that the dominant negative isoform, DNp63, which has been reported to be upregulated in several p63-positive malignancies, is not expressed in thyroid tumours.
TAp63a is expressed in thyroid cancer cell lines
To identify an in vitro model to study the role of TAp63a in thyroid cancer biology, we explored by RT-PCR the expression of p63 in a panel of thyroid cancer cell lines, representative of the three thyroid cancer histotypes (3 papillary, 2 follicular and 6 anaplastic) ( Fig. 2A ). Normal thyrocytes in primary culture were also studied ( Fig. 2A, B , C, on the left). The TAp63a transcript was present in 2 out of 3 papillary thyroid cancer cell lines (BC-PAP and 8505C), 1 out of 2 follicular thyroid cancer cell lines (FTC-133) and all (6/6) anaplastic thyroid cancer cell lines (FF-1, SW-1736, C-643, Hth-74, 8305C and AM-1) ( Fig. 2A) . Moreover, 3 cell lines (FTC-133, SW-1736 and C-643) were also faintly positive for the TAp63g transcript ( Fig. 2A) . In contrast, the DN-p63 transcript was not found in the thyroid cancer cell lines tested ( Fig. 2A) . In contrast, normal thyrocytes were negative for p63 transcript ( Fig. 2A , on the left).
In the same cell lines, we then evaluated p63 protein expression by western blot (Fig. 2B ) and found that the TAp63a protein was present in BC-PAP, 8505C, FTC-133, C643 and Hth-74 cells (Fig. 2B ). In contrast, in FF-1, SW-1736, 8305C and AM-1 cells, which were positive for TAp63a mRNA, the protein was not detected (Fig. 2B ). C-98 and FRO cells expressed neither TAp63a mRNA nor the protein ( Fig. 2A, B ). Data obtained are summarized in Table 2 . The TAp63g protein was not detected in any of the cell lines expressing the mRNA. A high expression of all three p63 protein isoforms (TAp63a, DNp63a and TAp63g) was observed in A431 cells, used as a positive inhibitor MG132, a faint band corresponding to TAp63a protein was observed (not shown). These findings suggest that in these cells the TAp63a protein is present, but its expression is decreased below detectable levels by proteasomal degradation. In these thyroid cancer cells, we then evaluated p63 localization by immunofluorescence using the 4A4 antibody ( Fig. 2C ). In C-98 cells (p63 negative, see Fig. 2A , B and Table 2 ) we did not detect any p63 immunoreactivity ( Fig. 2C) , whereas in FTC-133 and C-643 cells (p63 positive, see Fig. 2A , B and Table 2) , the p63 signal was localized in the nucleus, in a manner similar to that observed in the p63-positive cells A431 (Fig. 2C ). In accordance with the results obtained by immunohistochemistry, normal thyrocytes in primary culture did not display any p63 immunoreactivity (Fig. 2C , on the left).
These data indicate that TAp63a is present in most thyroid cancer cells in permanent culture, but not in normal thyrocytes, and confirm the data obtained in thyroid tissue specimens.
Endogenous p63 does not exert p53-like functions in thyroid cancer p63 is able to activate a pool of genes, which are also common targets of p53 and p73 (Sasaki et al. 2001) , Results presented are the combination of previous data and data obtained by RT-PCR and western blot in figure 2 . including p21Cip1, Bax and MDM2 (Zhu et al. 1998 , Lee & La Thangue 1999 , Nakano et al. 2000 . Doxorubicin is an effective DNA damaging agent, which leads to the activation of p53 and p73 and, as a consequence, to the transactivation of target genes. Hence, to explore the onco-suppressor activity of TAp63a, we exposed thyroid cancer cells to doxorubicin. To this end, we used cell lines with a genetic background suitable for our experiments, i.e. we selected FTC-133 and C-643 cells, which express TAp63a and p53 inactive mutants but not p73 ( Fig. 2 and Table 2 ). Hence, in these cells doxorubicin is expected to induce p21Cip1/Bax expression exclusively via TAp63a. As a positive control we employed the human breast cancer cell line MCF-7, which has a wild-type p53 and maintains a normal response to doxorubicin. As a negative control we used FF-1 thyroid cancer cells, harbouring mutated p53 (Frasca and p63 proteins ( Fig. 2 and Table 2 ).
In MCF-7 cells, exposure to doxorubicin increased the expression level of p53 and, as a consequence, led to the induction of the target gene p21 (Fig. 3A) . In contrast, doxorubicin neither significantly affected the TAp63a level in C-643 and FTC-133 cells (Fig. 3A) , nor caused the appearance of p63 protein in FF-1 cells (Fig. 3A) and C-98 cells (not shown). As a consequence, doxorubicin failed to increase p21Cip1 content in FF-1, C643, C-98 and FTC-133 thyroid cancer cell lines (Fig. 3A) . In accord with the failure of p21Cip1 induction (Fig. 3A) , doxorubicin failed to cause a significant G1 arrest in thyroid cancer cells (Fig. 3B) , independently of p63 status, whereas it did do so in MCF-7 cells, as expected. Moreover, doxorubicin treatment failed to induce the pro-apoptotic gene Bax and apoptosis in thyroid cancer cells (data not shown).
In accordance with the abrogation of p53 function (Blagosklonny 2002) , exposure to doxorubicin for 72 h induced a G2/M arrest in all four thyroid cancer cell lines (not shown), indicating that doxorubicin was used at an effective concentration. Taken together, these results indicate that in thyroid cancer cells TAp63a is not involved in the DNA damage response.
TA63a function is not restored by ectopic expression
Since DNA damage, following exposure to doxorubicin, was not able to increase the TAp63a level in thyroid cancer cells, we suspected a defect upstream of p63 induction. To address this issue, we induced TAp63a overexpression by transient transfection in C-98 (p63 negative, see Table 2 ) and FTC-133 (p63 positive, see Table 2 ) thyroid cancer cells. As a control, p53/p63 null human osteosarcoma cell line Saos-2 cells, which are commonly used as a model to study p53 family member functions (Yang et al. 1999 , Ghioni et al. 2002 , were also included. In all cell lines p53 was also transfected as a positive control (Fig. 4A ).
Immunofluorescence staining of transfected cells with anti-myc antibody revealed a correct localization of the ectopic TA-p63a in the cell nuclei (not shown). Western blot analysis showed that ectopic TAp63a was expressed in transfected cells and it was effective in inducing p21Cip1 (Fig. 4A) in Saos-2 cells. In contrast, TAp63a was almost ineffective in thyroid cancer cells (Fig. 4A) .
We then tested the effect of overexpressed TAp63a on cell cycle distribution in C-98 (p63 negative, see Table 2 ), FTC-133 (p63 positive, see Table 2 ) and Saos-2 (control) cells (Fig. 4B ). To this end, TAp63a or p53 were transiently transfected together with H2B-GFP to mark the transfected population. FACS analysis performed in the GFP-positive cells showed that TAp63a did not induce G1 arrest in thyroid cancer cells, whereas p53 did, in accordance with p21Cip1 induction (Fig. 4B) . In contrast, both TAp63a and p53 were able to elicit G1 arrest in control Saos-2 cells (Fig. 4B ). In addition, FACS analysis revealed that TAp63a did not increase the apoptotic population (subG1) in thyroid cancer cells (Fig. 4C ), whereas p53 did (Fig. 4C ). This increase, however, was less than 10% of the total population, in accordance with previous reports indicating that thyroid cancer cells are refractory to p53-induced apoptosis (Moretti et al. 1997 (Moretti et al. , 2000 . In control Saos-2 cells, both TAp63a and p53 significantly increased apoptosis (subG1 was approximately 50% of the total population) (Fig. 4C) .
These data indicate that even ectopic overexpression of TAp63a is not able to elicit p53-like responses in thyroid cancer cells and raises the question why this protein does not exert any tumour suppressor activity in these cells.
TAp63a does not interact with p53 mutants in thyroid cancer cells
Since transient transfection experiments suggested a possible defect intrinsic to TAp63a, we tested whether TAp63a protein in thyroid cancer cells is inhibited by the direct interaction with p53 mutants (Gaiddon et al. 2001 , Strano et al. 2002 . To this end, we performed co-immunoprecipitation experiments in p63 positive (C-643 and FTC-133), and p63 negative (C98) thyroid cancer cell lines, and in the A431 oesophageal cancer cell line (Park et al. 1994 ) as a positive control (Fig. 5) . In A431 cells we were able to detect p63 in anti-p53 immunoprecipitates (Fig. 5) , whereas we did not find p53/p63 co-immunoprecipitation in any thyroid cancer cell line (Fig. 5) .
These data indicate that the p53 mutants expressed in these thyroid cancer cell lines do not interact with p63.
p63 function is selectively abrogated in the TAp63a isoform
The p63 protein exists in various C-terminal splicing isoforms (a, b and g) and, at variance with p53, contains a C-terminal domain, which is a protein interaction module endowed with inhibitory function (Moll et al. 2001) . Such a domain is present in TAp63a but absent in TAp63b and TAp63g. Moreover, it has been reported that exon 13 alone, located at the p63 C-terminus and missing in TAp63b, may inhibit TAp63a transcriptional activity by interaction with unknown proteins (Ghioni et al. 2002) . To test whether the C-terminal inhibitory domain is involved in the inactivation of TAp63a in thyroid cancer cells, we compared the transactivation activity of ectopic TAp63a, TAp63b (lacking exon 13), TAp63g (lacking exons 11-14), DNp63a and p53 on the target genes p21Cip1, Bax and MDM2 in thyroid cancer cells and (Table 3) . Luciferase assays (expressed as a percent of maximal induction) revealed that TAp63a, TAp63b, TAp63g and p53 displayed comparable transactivation activity in Saos-2 cells, as previously reported (Table 3 ) (Ghioni et al. 2002) . In contrast, TAp63a displayed a weak transactivation activity in thyroid cancer cells (C-98, FF-1, C-643 and FTC-133), similar to that observed with the dominant negative isoform DNp63a (Table 3 ).
In accordance with the data obtained by the luciferase assay, western blot analysis of p21Cip1 showed that TAp63g consistently increased the level of p21Cip1 protein in both Saos-2 control cells and in C-98 and FTC-133 thyroid cancer cells, whereas TAp63a was effective in Saos-2 cells but did not increase p21Cip1 in thyroid cancer cells (Fig. 6A) . Anti-Myc western blots indicated that both ectopic TAp63a and TAp63g were expressed at a comparable level in transfected cells (Fig. 6A, middle panel) .
To test the onco-suppressor function of p63, we transfected C-98 (p63 negative) and FTC-133 (p63 positive) with p53, TAp63a and TAp63g together with H2B-GFP to mark the transfected population. Fortyeight hours after transfection, FACS analysis revealed that TAp63g arrested the cells in G1 to an extent similar to that of p53 (Fig. 6B) , whereas TAp63a was not effective, in accordance with the results obtained with the luciferase assays. In control Saos-2 cells, TAp63a, TAp63g and p53 were all effective, although to a variable extent, in inducing a G1 arrest (not shown).
These results suggest that TAp63a does not act as a typical p53 family member in thyroid cancer cells, which maintain a high responsiveness to the tumour suppressor activity of TAp63b and TAp63g.
TAp63a exerts a dominant negative effect on p53 activities
It is known that DNp63, the N-terminal truncated p63 isoform, is devoid of transactivation activity and is able to exert a dominant negative effect towards p53 family members (Yang et al. 1998 ). Since TAp63a displayed very poor transactivation activity in thyroid cancer cells, comparable to that of DNp63a, we tested whether TAp63a could antagonize p53 activities. Blot: anti-p63 4A4 Figure 5 Co-immunoprecipitation experiments for p53 and p63. Lysates from p63-positive 8505C, C-643, Hth-74 and FTC-133 thyroid cancer cells were immunoprecipitated (IP) with either anti-p63a (H129) or anti-p53 (DO-1) antibody and blotted with an anti-p63 monoclonal antibody (4A4). A431 cells were used as a positive control (on the left), whereas COS-1 cells transfected with TAp63a were used as a standard (on the right). No co-immunoprecipitation is evident in thyroid cancer cell lines. We transfected p21Cip1, Bax and MDM2 promoters together with p53, TAp63a and DNp63a in C-98, FF-1 (p63 negative, see Table 2 ), C-643, FTC-133 (p63 positive, see Table 2 ) thyroid cancer cells and in p53null Saos-2 cells. The ability of TAp63a to antagonize the effect of p53 was evaluated by luciferase assay (Table 4 ). In Saos-2 cells, TAp63a did not significantly affect the activity of p53 on reporter genes (Table 4) , whereas DNp63a exerted an antagonistic effect, as expected (Table 4 ). However, it was interesting to note that in Saos-2 cells the effect of TAp63a was not additive or synergistic with p53 (Table 4) . Surprisingly, TAp63a antagonized p53 transactivation activity to a variable extent in thyroid cancer cells (C-98, FF-1, C-643, FTC-133; Table 4 ), in a manner similar to that of DNp63a (Table 4 ).
Therefore, we tested whether TAp63a could also antagonize the effect of p53 on thyroid cancer cell viability (Fig. 7A) (Ozaki et al. 2003) . Transient co-transfection experiments with H2B-GFP to mark the transfected population revealed that TAp63a attenuated the effect of p53 on the reduction of cell number, in a manner similar to that of DNp63a (Fig. 7A ). In Saos-2 cells, used as a control, TAp63a did not influence this effect of p53 ( Fig. 7A) whereas DNp63a did, in accordance with the data obtained with the luciferase assays (Table 4 ). We then tested the effect of TAp63a on foci formation of C-98, FF-1, C-643 and FTC-133 thyroid cancer cells. Hence, we transfected p53, TAp63a or DNp63a into the above-mentioned cell lines and subjected them to antibiotic selection (Fig. 7B, C) . Transfection with p53 drastically reduced the number of foci (Fig. 7B, C) . No significant reduction of foci was observed in cells transfected with either TAp63a or DNp63a (Fig. 7B, C) . Interestingly, co-transfection with TAp63a inhibited the effect of p53 on foci, in a manner similar to that of DNp63a (Fig. 7B, C) .
Since these data were obtained by p63 overexpression, we tried an alternative approach aimed at reducing the expression of TAp63a (Fig. 8 ). To this end, we subjected the p63-positive FTC-133 cells, which display the highest level of TAp63a (Fig. 3A) , and the p63-negative C-98 cells (as a negative control) to p63 silencing by the siRNA technique (Fig. 8) . Forty-eight hours after incubation with siRNAs, we transfected p53 together with the p21Cip1 reporter. The luciferase assays revealed that p63 silencing in FTC-133 cells enhanced the p21Cip1 promoter response to increasing doses of p53 cDNA, whereas no difference was observed in the p63-negative C-98 cells, as expected (Fig. 8) . Taken together, these data suggest that in thyroid cancer cells TAp63a may have a tumour-promoting role by antagonizing p53 in a manner similar to that of the dominant negative isoform, DNp63a.
Discussion
The present results indicate that most thyroid cancers express TAp63a, while normal thyroid cells and benign adenomas do not. The expression of TAp63a in thyroid cancer has been assessed by different techniques, including RT-PCR, western blot and immunohistochemistry. Data obtained in malignant thyroid tissues were confirmed in thyroid cancer cell lines, which were then used as in vitro models to study TAp63a function in thyroid cancer. In these cells, we found that endogenous TAp63a does not play a p53like role, fails to induce the target genes p21Cip1, Bax and MDM2, and does not cause cell growth arrest and apoptosis. Even ectopic overexpression of TAp63a is not able to exert any tumour suppressor activity in thyroid cancer cells. These observations raise several questions about the possible role of TAp63a in thyroid tumorigenesis.
Evidence of p63 expression in human cancers is not novel and has already been reported in a variety of human malignancies, including thymomas, non-Hodgkin's lymphomas, bladder, breast, prostate and lung cancers (Moll et al. 2001) . It is noteworthy that p63 has also been detected in a small subset of papillary and anaplastic thyroid carcinomas (Preto et al. 2002) . Immunohistochemistry experiments performed in those studies, however, might have underestimated the real prevalence of p63 expression in thyroid tumours, because of the use of paraffinembedded specimens, in which the antigenic properties of p63 can be altered. In contrast, by examining frozen samples of thyroid cancer we found that the large majority was positive for p63 expression by immunohistochemistry, a probable effect of the better preservation of the p63 epitopes with the freezing process.
p63 up-regulation in human tumours (Okada et al. 2002) is often concomitant with the overexpression of the dominant negative isoform DNp63 (Crook et al. 2000 , Hibi et al. 2000 , Park et al. 2000 . In some The ability of p63 to antagonize the p53 transcriptional activity on reporter genes was evaluated by the luciferase assay as described in methods. Numbers indicate the meantS.E. of three separate experiments performed in duplicates and are expressed as percent of maximal induction.
tumours, DNp63 is preferentially expressed, suggesting that this p63 isoform may act as an oncogene (Crook et al. 2000 , Hibi et al. 2000 , Park et al. 2000 . However, a previous report showing TAp63 expression in gastric cancer suggests that TAp63 isoforms may also be involved in tumour progression (Tannapfel et al. 2001 ). This might be the case for thyroid tumours, where DNp63 is not expressed. Our studies indicate that in thyroid cancer TAp63a is devoid of any onco-suppressor activity. In fact, genotoxic stress caused by doxorubicin was not able to activate TAp63a in malignant thyroid cancer cells, suggesting that this p63 isoform was not involved in p53-like activities. Since no increase in TAp63a expression was observed after doxorubicin treatment, we first hypothesized an impaired signalling upstream of TAp63a itself. However, TAp63a overexpression, obtained by transient transfection, also failed to induce the target genes p21Cip1, Bax and MDM2, suggesting that the defect was either downstream or intrinsic to TAp63a itself. A defect downstream of p63 was ruled out with the ectopic expression of p53, TAp63b and TAp63g, which share similar downstream pathways with TAp63a. All these onco-suppressors were still able to transactivate target genes and to exert tumour suppressor activity in these thyroid cancer cells.
One possible inactivation mechanism intrinsic to the p63 protein is the interaction with p53 mutants (Gaiddon et al. 2001 , Strano et al. 2002 . In our hands, however, co-immunoprecipitation experiments performed in thyroid cancer cells excluded such interaction. Moreover, experiments performed in the p53-null thyroid cancer cell line SW1736 also ruled out the possibility of a p53 interference with TAp63a (not shown).
In thyroid cancer cells, only TAp63a is transcriptionally weak, since TAp63b and TAp63g display transcriptional activity similar to that of p53. Therefore, the onco-suppressor activity defect is restricted to the TAp63a isoform. One difference between p53 and p63 resides in the carboxyl tail: p63, in a similar manner to p73, contains a carboxyl terminus that undergoes alternative splicing and gives rise to different isoforms. Deletion studies have shown that the last 71 amino acids at the C-terminal domain (TI domain), which are missing in both TAp63b and TAp63g, are endowed with inhibitory properties towards p63 transcriptional activity (Serber et al. 2002) . This inhibition occurs by an intramolecular interaction between the TI domain and the transactivation domain (TA) located at the N-terminus of p63 (Serber et al. 2002) . This interaction is responsible for the occupancy of the TA domain, which, consequently, is no longer available for transactivation (Serber et al. 2002) . Moreover, previous evidence established a dominant negative capability of the TI domain, since DNp63a (endowed with TI), but not DNp63g (devoid of TI) is able to inhibit TAp63g activity (Yang et al. 1998 ). These results outline, therefore, the importance of the TI domain in the dominant negative activity of DNp63 isoforms. A previous report has also shown that the p63 C-terminal domain encoded by exon 13 (which is missing in TAp73b) exerts an inhibitory effect on TAp63a activity, possibly by interacting with various proteins (Ghioni et al. 2002) . It is also known that, although endowed with a very weak transcriptional activity, TAp63a is still able to bind DNA in a manner similar to that of p53 and the other more active p63 isoforms (Yang et al. 1998) . Taken together, this evidence suggests that in some cell contexts, such as in thyroid cancer cells, TAp63a may occupy the DNA binding sites of p53 responsive elements, thereby preventing occupancy by more transcriptionally active p53 family members. This interpretation could partially explain why TAp63a expression may antagonize p53-mediated tumour suppression in thyroid cancer cells, thus establishing an oncogenic role similar to that of DNp63a. Although this is the first report dealing with direct evidence of a dominant negative/pro-tumourigenic role of TAp63a, indirect evidence of this unsuspected TAp63a role is already present in the literature. Indeed, patients with mutations that introduce a premature stop codon in the TAp63a C-terminus show defects in hands and feet similar to those with mutations in the DNA binding domain (DBD) (Celli et al. 1999 ), suggesting that the loss of DNA binding capability by TAp63a (due to mutations in the DBD) has effects similar to those observed with TAp63a inappropriate activation due to the loss of the TI domain (stop codon). Therefore, both DNA binding and weak transactivation activities may be required for TAp63a to allow proper skeletal development, in order to avoid the premature apoptosis in skeletal precursors. In the light of these considerations, TAp63a should be able to antagonize either homologue (TAp63b and TAp63g) or paralogue (p53, TAp73) p53 family members, and TAp63a expression in thyroid cancer could be regarded as a mechanism aimed at inhibiting p53-mediated apoptosis.
The TI domain of p63a is very similar to that of p73a, but very different from that of p53 (Moll & Slade 2004) . Indeed, a similar antagonistic role against p53-mediated onco-suppression has also been reported for TAp73a in ovarian cancer (Vikhanskaya et al. 2000) and leukaemia cells (Freebern et al. 2003) . It is reasonable to suppose, therefore, that TAp63a and TAp73a, which are endowed with weaker transcriptional activity than p53, may acquire antagonistic properties against p53 in the presence of unknown co-repressor(s) present in some cancer types. This could partially explain why the dominant negative effect of TAp63a is not observed in Saos-2 cells, suggesting that this phenomenon may be cell contextdependent. In this situation, well-differentiated thyroid tumours, rarely harbouring p53 mutations, may take advantage of the expression of TAp63a and DNp73a , which may antagonize p53 and, at variance with p53, are resistant to MDM2-mediated degradation (Okada et al. 2002) .
The complexity of the p53 family protein network must be taken into account when considering gene therapy in thyroid cancer aimed at restoring the wild-type p53 status. More specifically: (a) unlike TAp63a, TAp63b and TAp63g are still effective in transactivating target genes and providing tumour suppressor functions in poorly differentiated thyroid cancer cells; (b) p63 proteins are strictly homophilic and are refractory to tetramerization with different members of the family (Moll & Slade 2004) and, therefore, at variance with wild-type p53, ectopic TAp63b and TAp63g are more resistant to the dominant negative effect of p53 mutants. Hence, adenoviral vectors carrying TAp63b and TAp63g should be tested in the anaplastic thyroid cancer cells harbouring p53 mutations since they may prove useful for designing possible anti-cancer therapies by gene delivery.
